Category Archives: Regulatory Communications

Class of One – Avoiding Warning Letters, Part II

According to FDA regulations, one cannot state a claim that one’s drug or biologic is superior to another unless there has been a head to head study demonstrating that superiority. That regulatory reality can be frustrating to communications professionals who … Continue reading

Posted in Regulatory Communications, Warning Letters | 1 Comment

Common Sense Confirmed

Common Sense Confirmed – Study Reveals Talking to the FDA is Good! – From the department of Dog Bites Man, the FDA issued a press release on February 9 revealing that pharmaceutical and biotech companies that communicate more frequently and earlier … Continue reading

Posted in Regulatory Communications | Comments Off on Common Sense Confirmed